ALK-Abelló A/S
As of the edition of 20 October 2026, ALK-Abelló A/S runs 4 drugs, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 3 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Epinephrine | none listed | 23 |
A route B row is one company at one target.
Where its trials are
- Immune system: 5 trials led
- Ear, nose and throat: 4 trials led
- Lungs and airways: 4 trials led